Barrons.com2d agobearish
Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
322last 24h
2136last 7d
379● bullish (7d)
187● bearish (7d)
204publishers
Stocktwits8d agobearish
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales FutureNovo now expects underlying sales and operating profit in the range of 0% to –6% for the year.